ArticleBrain tumor research and treatment2022
Clinical Features and Prognosis of Diffuse Midline Glioma: A Series of 24 Cases.
Article in Brain tumor research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- Comparative analysis of clinical characteristics and prognostic factors in adult and pediatric patients with H3K27M-mutant diffuse midline glioma.Neurosurgical review · 2026Article
- Prevalence and Clinicoradiopathological Characterization of H3 K27-Altered Diffuse Midline Gliomas in Adults-A Retrospective Observational Study.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Intracranial Retrograde Cerebrospinal Fluid Dissemination of H3 K27-altered Glioma.Journal of neurological surgery reports · 2026Article
- Diffuse midline glioma, H3K27-altered, mimicking central neurocytoma on MRI: A case report.Radiology case reports · 2026Article
- Frequency and outcomes of midline gliomas in a tertiary care hospital in Pakistan: a retrospective study.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- An Unusual Case of H3K27-Altered Diffuse Midline Glioma Presenting as a Third Ventricular Mass.Cureus · 2025Article
- Article
- Prognostic modeling for diffuse midline glioma: development and validation of a risk stratification nomogram using SEER and institutional cohorts.Frontiers in oncology · 2025Article
- Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort.Acta neuropathologica communications · 2024Article
- Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy.BMC cancer · 2024Article
- Isocitrate Dehydrogenase (IDH)-Mutant High-Grade Glioma in the Cerebellum: A Case Report.Cureus · 2024Article
- Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.CNS neuroscience & therapeutics · 2024Article
- Fulminant hemorrhagic course of a thalamic H3 K27-altered diffuse midline glioma in an adult patient: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- A first-in-human peptide vaccine targeting H3K27M; encouraging early findings in 8 adults with diffuse midline glioma.Neuro-oncology · 2024Article
- The landscape of current research on pediatric diffuse midline glioma: a quantitative analysis of shifts, leaders, and future avenues.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Review
- Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.CNS neuroscience & therapeutics · 2023Article
- Decoding Diffuse Midline Gliomas: A Comprehensive Review of Pathogenesis, Diagnosis and Treatment.Cancers · 2023Review
- Review
- Neuro-ophthalmological disturbances in pediatric posterior fossa tumors: Prevalence, risk factors, and outcomes.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiffuse midline glioma (DMG) which occurs in midline structures and characterized by harboring K27M mutation in genes encoding the histone 3 protein is classified as World Health Organization (WHO) grade IV regardless of histological findings and has a poor prognosis. Nevertheless, because of its relatively rare incidence compared with other high-grade gliomas, a comprehensive description encompassing clinical features and genomic profiles of DMG is still lacking.
methodsIn this study, we analyzed data of 24 patients who were diagnosed as DMG which was confirmed by surgical specimens in both pediatric and adult patients. We described the clinical outcomes of patients with DMG and their genomic profiles through a retrospective analysis of 24 patients with DMG.
resultsThe clinical characteristics of the 24 patients with DMG were analyzed. Ten patients (41%) underwent tumor resection and 14 patients (59%) underwent tumor biopsy. The median overall survival was 10.4 months (95% confidence interval [CI], 8.4 to 12.5) and progression free survival was 3.9 months (95% CI, 2.6 to 5.2). Fifteen patients (62%) were accompanied by hydrocephalus. None of the patient, tumor, or treatment factors had any significant associated with survival. In both immunohistochemistry staining (n=24) and targeted next generation sequencing (n=15), TP53 mutation was the most common genetic mutation (25% and 46%, respectively) found in the patients except alterations in histone 3 protein.
conclusionAlthough surgical treatment of patient with DMG does not affect the overall survival prognosis, it can help improve the patient's accompanying neurological symptoms in some limited cases. Hydrocephalus is often accompanied with DMG and treatment for hydrocephalus is often also required. Multidisciplinary therapeutic approach is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.